

AMENDMENTS TO THE CLAIMS

Please cancel Claims 65-68 and amend Claims 69, 72, 75 and 78 as follows:

1-68 (Canceled)

69. (Currently Amended) An isolated protein encoded by a nucleic acid molecule comprising a nucleic acid sequence at least about 95% identical to a nucleic acid sequence selected from SEQ ID NO:9 or SEQ ID NO:19, wherein said protein is capable of binding a CTLA4 or CD28 protein or is capable of co-stimulating T-cells in the presence of an antigenic peptide.

70. (Previously presented) The isolated protein of Claim 69, wherein said protein is encoded by a nucleic acid molecule comprising a nucleic acid sequenced selected from SEQ ID NO:9 or SEQ ID NO:19.

71. (New Previously presented) The isolated protein of Claim 69, wherein said protein is encoded by a nucleic acid molecule consisting of SEQ ID NO:9 or SEQ ID NO:19.

72. (Currently amended) A therapeutic composition comprising the isolated protein of Claim 69, wherein said composition, when administered to a canid non-human animal, regulates T-cell mediated immune responses in said canid non-human animal.

73. (Previously presented) The therapeutic composition of Claim 72, wherein said composition comprises a component selected fm an excipient, an adjuvant or a carrier.

74. (Canceled)

75. (Currently amended) An isolated protein comprising an amino acid sequence at least about 95% identical to an amino acid sequence selected from SEQ ID NO:7 or SEQ ID NO:17, wherein said isolated protein is capable of binding a CTLA4 or CD28 protein or is capable of co-stimulating T-cells in the presence of an antigenic peptide.

76. (Previously presented) The isolated protein of Claim 75, wherein said protein comprises an amino acid sequence selected from SEQ ID NO:7 or SEQ ID NO:17.

77. (Previously presented) The isolated protein of Claim 75, wherein said protein consists of an amino acid sequence selected from SEQ ID NO:7 or SEQ ID NO:17.

78. (Currently amended) A therapeutic composition comprising the isolated protein of Claim 75, wherein said composition, when administered to a canid non-human animal, regulates T-cell mediated immune responses in said canid non-human animal.

79. (Previously presented) The therapeutic composition of Claim 78, wherein said composition comprises a component selected from an excipient, an adjuvant or a carrier.

80. (Canceled)